These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Development of an Intracellular Screen for New Compounds Able To Inhibit Mycobacterium tuberculosis Growth in Human Macrophages. Sorrentino F; Gonzalez del Rio R; Zheng X; Presa Matilla J; Torres Gomez P; Martinez Hoyos M; Perez Herran ME; Mendoza Losana A; Av-Gay Y Antimicrob Agents Chemother; 2016 Jan; 60(1):640-5. PubMed ID: 26503663 [TBL] [Abstract][Full Text] [Related]
24. Strategies in anti-Mycobacterium tuberculosis drug discovery based on phenotypic screening. Grzelak EM; Choules MP; Gao W; Cai G; Wan B; Wang Y; McAlpine JB; Cheng J; Jin Y; Lee H; Suh JW; Pauli GF; Franzblau SG; Jaki BU; Cho S J Antibiot (Tokyo); 2019 Oct; 72(10):719-728. PubMed ID: 31292530 [TBL] [Abstract][Full Text] [Related]
25. Determination of compound kill kinetics against Mycobacterium tuberculosis. Early J; Alling T Methods Mol Biol; 2015; 1285():269-79. PubMed ID: 25779322 [TBL] [Abstract][Full Text] [Related]
26. Identification of 2-Amino Benzothiazoles with Bactericidal Activity against Mycobacterium tuberculosis. Bonnett S; Jee JA; Chettiar S; Ovechkina Y; Korkegian A; Greve E; Odingo J; Parish T Microbiol Spectr; 2023 Feb; 11(1):e0497422. PubMed ID: 36688635 [TBL] [Abstract][Full Text] [Related]
27. Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis. Karabanovich G; Zemanová J; Smutný T; Székely R; Šarkan M; Centárová I; Vocat A; Pávková I; Čonka P; Němeček J; Stolaříková J; Vejsová M; Vávrová K; Klimešová V; Hrabálek A; Pávek P; Cole ST; Mikušová K; Roh J J Med Chem; 2016 Mar; 59(6):2362-80. PubMed ID: 26948407 [TBL] [Abstract][Full Text] [Related]
29. A class of hydrazones are active against non-replicating Mycobacterium tuberculosis. Bonnett SA; Dennison D; Files M; Bajpai A; Parish T PLoS One; 2018; 13(10):e0198059. PubMed ID: 30332412 [TBL] [Abstract][Full Text] [Related]
30. Bioluminescence for assessing drug potency against nonreplicating Mycobacterium tuberculosis. Vocat A; Hartkoorn RC; Lechartier B; Zhang M; Dhar N; Cole ST; Sala C Antimicrob Agents Chemother; 2015 Jul; 59(7):4012-9. PubMed ID: 25896710 [TBL] [Abstract][Full Text] [Related]
31. Synthetic calanolides with bactericidal activity against replicating and nonreplicating Mycobacterium tuberculosis. Zheng P; Somersan-Karakaya S; Lu S; Roberts J; Pingle M; Warrier T; Little D; Guo X; Brickner SJ; Nathan CF; Gold B; Liu G J Med Chem; 2014 May; 57(9):3755-72. PubMed ID: 24694175 [TBL] [Abstract][Full Text] [Related]
33. Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening. Manjunatha UH; Smith PW Bioorg Med Chem; 2015 Aug; 23(16):5087-97. PubMed ID: 25577708 [TBL] [Abstract][Full Text] [Related]